Skip to main content
COSMO Pharmaceuticals N.V. logo

COSMO Pharmaceuticals N.V. — Investor Relations & Filings

Ticker · COPN ISIN · NL0011832936 LEI · 724500OX0EBQRYTVV639 SW Manufacturing
Open in API
Filings indexed 169 across all filing types
Latest filing 2022-10-20 Regulatory Filings
Country NL Netherlands
Listing SW COPN

About COSMO Pharmaceuticals N.V.

https://www.cosmopharma.com/

COSMO Pharmaceuticals N.V. is a specialty pharmaceutical company focused on developing and commercializing products in gastroenterology, dermatology, and healthtech. The company's portfolio is built around its proprietary MMX® technology, a platform for the targeted delivery of active ingredients in the colon. Key products include GI Genius™, an AI-powered device for endoscopy; Winlevi®, a topical treatment for acne; and therapies for inflammatory bowel diseases such as Lialda®/Mezavant® and Uceris®/Cortiment®. In addition to its own product pipeline, Cosmo provides contract manufacturing services, including process assessment, technology transfer, stability testing, and market release for pharmaceutical products.

Recent filings

Filing Released Lang Actions
Cosmo announces FDA grants orphan-drug designation of rifamycin for treatment of pouchitis
Regulatory Filings Classification · 100% confidence The document is a press release dated 20.10.2022 announcing that the FDA granted orphan-drug designation for rifamycin for the treatment of pouchitis. This type of announcement, detailing a specific regulatory event (FDA designation) and its implications for a drug pipeline, is a general corporate announcement. It is not a full financial report (10-K, IR), a management discussion (MDA), an earnings release (ER), or a specific shareholder vote result (DVA). Since it is a significant regulatory/pipeline update that doesn't fit the more specific categories like M&A (TAR) or Capital Change (CAP), it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for miscellaneous regulatory announcements not covered elsewhere. Given the document length (under 5,000 characters) and its nature as an announcement of an event rather than the full regulatory filing itself, RNS is the most appropriate classification.
2022-10-20 English
Cosmo erhält von der FDA den Orphan-Drug-Status für  Rifamycin zur Behandlung von Pouchitis
Legal Proceedings Report Classification · 99% confidence The document is a press release dated 20.10.2022 announcing that the FDA granted Orphan-Drug Status to Rifamycin for the treatment of Pouchitis. It contains key business updates, management commentary (CEO quote), and a financial calendar. This type of announcement, focusing on a specific regulatory milestone (Orphan Drug Designation) and providing key highlights rather than comprehensive financial statements (like a 10-K or IR), aligns best with an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific, material announcement about regulatory progress, it is more specific than a general RNS. However, it is not a full earnings report (ER) or a transcript (CT). Given the nature of the announcement—a significant regulatory event update—it functions as a material disclosure. In the context of the provided definitions, if it's not a formal financial report (10-K, IR, MRQ), it often falls under a general announcement category. Since it is a specific, material, non-financial-statement update, and there isn't a perfect 'Regulatory Update' code, I will evaluate the closest fit. It is not a Director's Dealing (DIRS), Dividend (DIV), or Capital Change (CAP). It is a specific regulatory/product development update. If this were a US filer, it might be an 8-K item. Among the choices, 'RNS' (Regulatory Filings - general regulatory announcements and fallback) is the most appropriate general category for a press release detailing a specific FDA action that isn't a full financial report or a specific management/governance filing. However, since it is a press release announcing a key development, and it is short and focused, it is often classified as an Earnings Release (ER) if it's the primary communication vehicle for material news, or RNS if it's purely regulatory. Given the structure and content (FDA status update), RNS is the safest fallback for a non-standard report announcement.
2022-10-20 German
GI Genius™ named to FORTUNE 2022 “Change the World” list
Regulatory Filings Classification · 100% confidence The document is a short press release dated 12.10.2022 announcing that a product (GI Genius™) was named to the FORTUNE 2022 “Change the World” list. It contains company boilerplate, contact information, and an upcoming calendar. It is not a comprehensive financial report (like 10-K or IR), a transcript (CT), or a specific regulatory filing like a Director's Dealing (DIRS) or Dividend Notice (DIV). Since it is a general announcement of news that doesn't fit the other specific categories (like ER, which is for financial results), it falls best under the general regulatory announcement category, which is RNS (Regulatory Filings), as per the fallback rule for miscellaneous announcements.
2022-10-12 English
GI Genius™ wurde in die FORTUNE 2022-Liste «Change the World» aufgenommen
Regulatory Filings Classification · 100% confidence The document is a press release dated 12.10.2022, announcing that Cosmo Pharmaceuticals' partner, Medtronic, had the GI Genius™ module included in the FORTUNE 2022 'Change the World' list. It contains company updates, forward-looking statements, and contact information, typical of a general corporate announcement. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific financial report (IR, AR). Since it is a general, non-specific corporate announcement that doesn't fit the other defined categories (like DIRS, DIV, CAP, etc.), the most appropriate fallback category is Regulatory Filings (RNS), which serves as the general regulatory announcement category.
2022-10-12 German
Medtronic wins U.S. Department of Veterans Affairs contract to provide GI Genius™ intelligent endoscopy module for artificial intelligence (AI) assisted colon cancer screening
Regulatory Filings Classification · 100% confidence The document is a short announcement dated 06.10.2022, detailing a contract award involving Medtronic and the U.S. Department of Veterans Affairs concerning the GI Genius™ module. It includes commentary from the CEO and directs the reader to Medtronic's press release for full details ("Please read full details in Medtronic’s press release [here]"). The text is brief (4311 characters) and functions as a notification about an event/development rather than being a comprehensive financial report (like 10-K or IR) or a formal regulatory filing. Since it is an announcement of news that doesn't fit the specific categories like Director's Dealing (DIRS), Dividend (DIV), or Capital Change (CAP), it falls best under the general Regulatory Filings/Announcements category, which serves as a fallback for miscellaneous news releases that are not earnings releases (ER) or formal reports. Given the nature of the content (a business development announcement), RNS is the most appropriate general regulatory announcement code.
2022-10-06 English
Medtronic erhält Auftrag des US-Ministeriums für Veteranen-Angelegenheiten zur Lieferung des intelligenten Endoskopie-Moduls GI Genius™ für die durch KI unterstützte Darmkrebsvorsorge
Regulatory Filings Classification · 100% confidence The document is a short announcement dated October 6, 2022, originating from Cosmo Pharmaceuticals N.V. It explicitly states that Medtronic released a 'Medienmitteilung' (media release) regarding a contract win for the GI Genius™ module. The text itself summarizes this external announcement and includes a link to read the 'vollständigen Details in der Medienmitteilung von Medtronic'. Since the document is short (under 5,000 characters) and its primary function is to announce the publication of another piece of information (Medtronic's press release), it fits the definition of a Report Publication Announcement (RPA). It is not the full financial report (10-K or IR) nor a standard earnings release (ER), but an announcement about related news/publication.
2022-10-06 German

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.